Seikagaku (4548) · RiskRestated
Dependence on Joint-Function Improvement Agents and Ophthalmic Surgical Aids
First written in FY2016. 1 of 2 entries say "Restated". Latest entry: FY2017.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Revenue dependence on flagship product Cuenote FCA theme 78 companies write about · 79 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
29 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 78 companies compared. The sentences above are computed from all 78.Full recordFilings, disclosures and news, newest first
- FY2017RestatedAnnual report
「More than 90% of pharmaceutical business revenue in the current period came from joint function improvement agents and ophthalmic surgical aids, including overseas sales.」
Reiterates the concentration of pharmaceutical business revenue in joint function improvement agents and ophthalmic surgical aids. - FY2016First statedAnnual report
「Treatments for improving joint function and ophthalmic surgical aids, including overseas sales, accounted for more than 90% of pharmaceutical business sales in the fiscal year.」
The risk is that the company's performance may be affected if major products develop serious adverse effects or manufacturing or sales problems.